Cox Capital Mgt LLC Has $1.93 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Cox Capital Mgt LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 0.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,870 shares of the company’s stock after selling 88 shares during the period. Cox Capital Mgt LLC’s holdings in Zoetis were worth $1,934,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ZTS. Cherry Creek Investment Advisors Inc. boosted its holdings in shares of Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after buying an additional 58 shares during the last quarter. Grove Bank & Trust lifted its stake in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock valued at $2,298,000 after acquiring an additional 61 shares during the last quarter. Hancock Whitney Corp grew its position in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares during the period. Strategy Asset Managers LLC increased its stake in shares of Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares during the last quarter. Finally, Edge Capital Group LLC raised its holdings in shares of Zoetis by 3.7% in the 2nd quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock valued at $310,000 after purchasing an additional 64 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $164.31 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The stock has a market capitalization of $74.13 billion, a P/E ratio of 30.89, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89. The business’s 50 day simple moving average is $171.31 and its two-hundred day simple moving average is $180.16.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.36 earnings per share. Analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.